FRANKFURT (dpa-AFX) – What Bayer investors (Bayer) have been hoping for since the beginning of December 2025 at the latest has now happened: the US Supreme Court actually accepted the “Durnell” glyphosate case for review on Friday evening German time. This increases the prospects of a landmark judgment in the years-long legal dispute over the weed killer.
It would have a signaling effect for another 67,000 cases that were included in the provision of 6.5 billion euros in the most recent quarterly report, wrote Chris Counihan from the investment bank Jefferies on Sunday afternoon. Bayer hopes to clarify whether federal law regarding warning labels when selling weed killers overrides state law.
Bayer shares responded to the US Supreme Court’s acceptance after trading on the Tradegate trading platform on Friday evening by jumping 6 percent above the Xetra close to 44.13 euros.
At the beginning of December, the price rose by up to 15 percent when the so-called Solicitor General – a kind of attorney general for the US government – supported the company’s request for the “Durnell” case to be examined by the US Supreme Court. At that time, the shares climbed above 35 euros for the first time since the beginning of 2024. Since then, they have expanded their recovery rally by a further 19 percent, and the bottom that has formed after years of price slides is becoming increasingly stable.
The glyphosate case has weighed on Bayer since it took over the US agricultural chemical company Monsanto in 2018. The legal disputes over alleged cancer risks have already cost billions of euros and have had a heavy impact on the share price./ag/zb
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising